Edgar Filing: EAGLE PHARMACEUTICALS, INC.

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

SCHREIBER ALAIN

2. Issuer Name and Ticker or Trading Symbol
EAGLE PHARMACEUTICALS, INC. [EGRX]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O PROQUEST INVESTMENTS, L.P., 2430 VANDERBILT BEACH ROAD, 108-190

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2014

(Street)

NAPLES, FL 34109

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.001 par value	02/18/2014		C		1,927,986	A	⁽¹⁾	1,966,987	I	By ProQuest Investments IV, L.P. ⁽²⁾
Common Stock, $0.001 par value	02/18/2014		C		1,028,613	A	⁽¹⁾	2,995,600	I	By ProQuest Investments IV, L.P. ⁽²⁾
Common Stock, $0.001 par value	02/18/2014		C		850,520	A	⁽¹⁾	3,846,120	I	By ProQuest Investments IV, L.P. ⁽²⁾
Common Stock, $0.001 par value	02/18/2014		C		569,538	A	⁽¹⁾	4,415,658	I	By ProQuest Investments IV, L.P. ⁽²⁾
Common Stock, $0.001 par value	02/18/2014		X		21,837	A	⁽¹⁾	4,437,495	I	By ProQuest Investments IV, L.P. ⁽²⁾
Common Stock, $0.001 par value	02/18/2014		P		333,333	A	$ 15	4,770,828	I	By ProQuest Investments IV, L.P. ⁽²⁾
Common Stock, $0.001 par value	02/18/2014		C		62,575	A	⁽¹⁾	62,575	I	By ProQuest Management LLC Plans ⁽³⁾
Common Stock, $0.001 par value	02/18/2014		C		9,359	A	⁽¹⁾	71,934	I	By ProQuest Management LLC Plans ⁽³⁾
Common Stock, $0.001 par value	02/18/2014		X		357	A	⁽⁴⁾	72,291	I	By ProQuest Management LLC Plans ⁽³⁾
Common Stock, $0.001 par value								9,360	I	By ProQuest Management LLC ⁽⁵⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series A Convertible Preferred Stock

⁽¹⁾

02/18/2014

1,927,986 ⁽⁶⁾

⁽¹⁾

⁽⁷⁾

Common Stock

1,927,986 ⁽⁶⁾

⁽¹⁾

By ProQuest Investments IV, L.P. ⁽²⁾

Series B Convertible Preferred Stock

⁽¹⁾

02/18/2014

1,028,613 ⁽⁶⁾

⁽¹⁾

⁽⁷⁾

Common Stock

1,028,613 ⁽⁶⁾

⁽¹⁾

By ProQuest Investments IV, L.P. ⁽²⁾

Series B-1 Convertible Preferred Stock

⁽¹⁾

02/18/2014

850,520 ⁽⁶⁾

⁽¹⁾

⁽⁷⁾

Common Stock

850,520 ⁽⁶⁾

⁽¹⁾

By ProQuest Investments IV, L.P. ⁽²⁾

Series C Convertible Preferred Stock

⁽¹⁾

02/18/2014

569,538 ⁽⁶⁾

⁽¹⁾

⁽⁷⁾

Common Stock

569,538 ⁽⁶⁾

⁽¹⁾

By ProQuest Investments IV, L.P. ⁽²⁾

Series C Warrants

⁽⁸⁾

02/18/2014

98,368 ⁽⁴⁾

⁽⁸⁾

Common Stock

98,368 ⁽⁸⁾

⁽⁸⁾

By ProQuest Investments IV, L.P. ⁽²⁾

Series B-1 Convertible Preferred Stock

⁽¹⁾

02/18/2014

62,575 ⁽⁶⁾

⁽¹⁾

⁽⁷⁾

Common Stock

62,575 ⁽⁶⁾

⁽¹⁾

By ProQuest Management LLC Plans ⁽³⁾

Series C Convertible Preferred Stock

⁽¹⁾

02/18/2014

9,359 ⁽⁶⁾

⁽¹⁾

⁽⁷⁾

Common Stock

9,359 ⁽⁶⁾

⁽¹⁾

By ProQuest Management LLC Plans ⁽³⁾

Series C Warrants

⁽⁸⁾

02/18/2014

1,614 ⁽⁸⁾

⁽⁸⁾

Common Stock

1,614 ⁽⁸⁾

⁽⁸⁾

By ProQuest Management LLC Plans ⁽³⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
SCHREIBER ALAIN C/O PROQUEST INVESTMENTS, L.P. 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109	X	X

Signatures

/s/ Scott Tarriff, Attorney-in-Fact		02/20/2014
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series C Convertible Preferred stock automatically converted into one share of the Issuer's Common Stock on a 6.41-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
(2)	The shares are owned by ProQuest Investments IV, L.P. ("Investments IV"), of which ProQuest Associates IV LLC ("Associates IV") is the general partner. Jay Moorin and Alain Schreiber are managing members of Associates IV. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
(3)	The shares are held in a ProQuest Management LLC Defined Benefit Pension Plan ("DBPP") FBO Jay Moorin and a ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Jay Moorin and Alain Schreiber are trustees of the ProQuest Management LLC DBPP FBO Jay Moorin and the ProQuest Management LLC Salary Savings Plan FB0 Jay Moorin and for the benefit of certain other individuals. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
(4)	In accordance with their terms, the Series C Warrants (the "Warrants") were net exercised immediately prior to consummation of the Issuer's initial public offering into shares of Common Stock on a 6.41-for-1 basis.
(5)	The shares are owned by ProQuest Management LLC ("ProQuest Management"). The Reporting Person is a managing member of ProQuest Management. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities
(6)	Reflects a 1-for-6.41 reverse stock split, pursuant to which each share of preferred stock became convertible into 1/6.41 of a share of common stock.
(7)	The expiration date is not relevant to the conversion of these securities.
(8)	In accordance with their terms, the Series C Warrants (the "Warrants") were net exercised at an exercise price of $11.67 immediately prior to closing of the Issuer's initial public offering into shares of common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.